Masimo (NASDAQ:MASI) Releases Earnings Results, Beats Estimates By $0.38 EPS

Masimo (NASDAQ:MASI) issued its quarterly earnings results on Tuesday. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38, Zacks reports. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%.

Masimo Stock Down 1.6 %

Shares of MASI stock traded down $2.99 on Thursday, hitting $187.48. 175,353 shares of the stock were exchanged, compared to its average volume of 501,619. The firm has a market capitalization of $10.04 billion, a P/E ratio of 128.99 and a beta of 1.02. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $192.62. The business has a 50-day moving average of $172.95 and a 200 day moving average of $153.10.

Analyst Ratings Changes

A number of research analysts recently issued reports on MASI shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday. Wells Fargo & Company increased their price target on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Finally, Piper Sandler raised their price objective on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.